Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999292 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of 68Ga-R8760
A Phase 1 study, sponsored by Radionetics Oncology.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT05999292 is a Phase 1 study that was terminated before completion, run by Radionetics Oncology. The registered enrollment target is 11 participants.
The verdict
NCT05999292, a Phase 1 study, was terminated before completion, sponsored by Radionetics Oncology.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
Interventions
- DRUG 68Ga-R8760 injection at pre-defined dose levels
- DRUG 68Ga-R8760 injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2023-09-11 |
| Est. Completion | 2024-05-23 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05999292
The ClinicalTrials.gov registry entry for NCT05999292 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Radionetics Oncology, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 68Ga-R8760 injection at pre-defined dose levels is the first listed.
NCT05999292 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05999292 about?
NCT05999292 is a clinical study titled "Phase 1 Study of 68Ga-R8760". A Phase 1 Safety and Dosimetry Study of 68Ga-R8760 in Patients with Adrenocortical Carcinoma and Healthy Volunteers
What is the current status of trial NCT05999292?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2023-09-11. Estimated completion is 2024-05-23.
What interventions are being tested in trial NCT05999292?
The interventions under investigation include: 68Ga-R8760 injection at pre-defined dose levels (DRUG), 68Ga-R8760 injection (DRUG).
Who is sponsoring clinical trial NCT05999292?
This trial is sponsored by Radionetics Oncology, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.